bluebird bio (NASDAQ:BLUE) Earns Sell Rating from Analysts at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.

BLUE has been the subject of a number of other research reports. Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a report on Friday, November 15th. Barclays reduced their target price on shares of bluebird bio from $4.00 to $2.00 and set an “overweight” rating on the stock in a report on Friday, November 15th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a research note on Monday, September 16th. Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $3.00 to $0.50 in a research note on Friday, November 15th. Finally, Robert W. Baird lowered their target price on bluebird bio from $7.00 to $6.00 and set an “outperform” rating for the company in a research report on Thursday, August 15th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $3.03.

bluebird bio Trading Down 8.4 %

Shares of bluebird bio stock opened at $0.31 on Monday. The firm’s 50-day moving average price is $0.48 and its two-hundred day moving average price is $0.78. The company has a market capitalization of $59.32 million, a price-to-earnings ratio of -0.17 and a beta of 0.76. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. bluebird bio has a 12-month low of $0.30 and a 12-month high of $5.53.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. The firm had revenue of $18.57 million during the quarter. On average, analysts forecast that bluebird bio will post -1.41 earnings per share for the current fiscal year.

Institutional Trading of bluebird bio

A number of large investors have recently bought and sold shares of BLUE. Allegheny Financial Group LTD bought a new stake in shares of bluebird bio during the 2nd quarter valued at about $25,000. Price T Rowe Associates Inc. MD lifted its stake in bluebird bio by 113.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 54,714 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 29,113 shares during the period. Bayesian Capital Management LP bought a new position in shares of bluebird bio during the 1st quarter worth approximately $52,000. American International Group Inc. grew its position in shares of bluebird bio by 77.4% during the 1st quarter. American International Group Inc. now owns 94,371 shares of the biotechnology company’s stock worth $121,000 after buying an additional 41,177 shares during the period. Finally, State Street Corp increased its stake in shares of bluebird bio by 1.1% in the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after acquiring an additional 43,382 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.